己酮可可碱（BL 191）口服治疗弱精子症。

Pentoxifylline (BL 191) by oral administration in the treatment of asthenozoospermia.

作者信息

Aparicio N J, Schwarzstein L, de Turner E A

出版信息

Andrologia. 1980 May-Jun;12(3):228-31. doi: 10.1111/j.1439-0272.1980.tb00617.x.

DOI:10.1111/j.1439-0272.1980.tb00617.x

Abstract

The aim of this trial was to study the effects on semen of pentoxifylline administered chronically per os to patients with normogonadotropic asthenozoospermia. Fifteen infertile men (age 22 to 44 years) were incorporated. Each subject was submitted to a treatment with pentoxifylline per os at a dose of 1,200 mg per day during no less than four months (x plus or minus SE 6.6 plus or minus 0.7 months). Assessment of the results was performed by serial spermatograms performed during and up to three months after treatment. The results showed a significant improvement of the percentages of forwardly progressive spermatozoa and of live and motile spermatozoa. Five of the patients achieved a normalization of semen (frank improvement) and seven a significant improvement in comparison to the initial values. Pregnancy was obtained by two patients. Pentoxifylline could be a useful alternative for the treatment of patients with normogonadotropic asthenozoospermia.

摘要

本试验的目的是研究对促性腺激素正常的弱精子症患者经口长期给予己酮可可碱对精液的影响。纳入了15名不育男性（年龄22至44岁）。每位受试者接受经口给予己酮可可碱的治疗，剂量为每日1200毫克，持续不少于四个月（x±SE 6.6±0.7个月）。通过在治疗期间及治疗后长达三个月进行的系列精液检查来评估结果。结果显示，向前运动精子、活精子和活动精子的百分比有显著改善。5名患者精液恢复正常（明显改善），7名患者与初始值相比有显著改善。两名患者成功受孕。己酮可可碱可能是治疗促性腺激素正常的弱精子症患者的一种有用的替代药物。